Uterine Cancer Diagnostic Testing Market

Uterine Cancer Diagnostic Testing Market Outlook (2024 to 2034)

The global uterine cancer diagnostic testing market size is expected to reach a size of US$ 3.23 billion in 2024. The market has been forecasted to climb to a value of US$ 6.76 billion by the end of 2034, expanding at a CAGR of 7.7% over the next ten years.

Uterine cancer diagnostic tests include ultrasound scanning, biopsy procedures, and blood tests. Utilizing sound waves, ultrasound scanning tests produce images of the uterus and ovaries. Abdominal and transvaginal ultrasound scanning are the two types of ultrasound scanning used in uterine cancer diagnostic tests. While transvaginal scanning involves inserting a transducer wand into the vagina to scan or create an image, abdominal scanning involves scanning a full bladder across the abdomen using a tiny device called a transducer.

Key Market Growth Drivers

• The need for diagnostic testing to identify and treat uterine cancer early is increasing as the disease's incidence rises worldwide.
• Precision and effectiveness of diagnosing uterine cancer have increased due to technological developments in genetic testing, biomarker identification, and imaging methods (such as MRI and ultrasound).
• Demand for diagnostic testing among older women is predicted to rise in tandem with the growing global aging population and the rising incidence of uterine cancer.
• Public health campaigns and initiatives promoting awareness of women's health issues, particularly uterine cancer, and encouraging early detection through routine screenings are contributing to the expansion of the uterine cancer diagnostic testing market size.
• Funding for uterine cancer diagnostic testing programs is frequently included in government initiatives aimed at cancer prevention, screening, and treatment.

Report Attribute	Details
Uterine Cancer Diagnostic Testing Market Size (2024E)	US$ 3.23 Billion
Projected Market Value (2034F)	US$ 6.76 Billion
Global Market Growth Rate (2024 to 2034)	7.7% CAGR
Latin America Market Growth Rate (2024 to 2034)	4.8% CAGR
North America Market Growth Rate (2034)	5.6% CAGR
Specialized Clinics Segment Value (2024)	US$ 653.7 Million
Biopsy Segment Value (2024)	US$ 1.81 Billion
Key Companies Profiled	Ariad Pharmaceuticals, Inc.; Abbott Laboratories; Becton, Dickinson & Co.; GlaxoSmithKline Plc; Merck & Co., Inc.; Novartis AG; Sanofi; Siemens Healthcare Inc.; Roche Ltd.; MiMARK Diagnostics.

Why is There an Uptick in Uterine Cancer Diagnostic Testing?

“Increasing Awareness of Early Diagnosis and Intervention for Uterine Cancer”

Risk factors for uterine cancer development include obesity, hyperplasia, and excessive drug use for breast cancer treatment. One of the main signs of endometrial cancer is abnormal vaginal bleeding, followed by pelvic pain and sudden vaginal discharge. Uterine sarcoma is diagnosed at a later stage and exhibits no symptoms, in contrast to endometrial carcinoma.

Blood tests, biopsy procedures, and ultrasound scanning are all part of the diagnostic testing for uterine cancer. Utilizing sound waves, ultrasound scanning tests produce images of the uterus and ovaries.

What are the Challenges for Uterine Cancer Diagnostic Testing?

“Ambiguous Early-Stage Symptoms and Disparities in Healthcare Infrastructure”

Early-stage uterine cancer symptoms are ambiguous or similar to those of other benign conditions that are causing diagnostic delays. In contrast to certain other cancers (such as cervical cancer detected by Pap smears), there is no common test to identify uterine cancer in women who do not exhibit any symptoms, which causes symptoms to not show up until later.

It is possible for certain diagnostic procedures such as biopsies and imaging studies, to incorrectly identify between benign and malignant uterine conditions, which results in false positives or negatives. Inequalities in the infrastructure and availability of advanced diagnostic tests are also preventing some regions thus delaying diagnosis and treatment.

Country-wise Insights

Europe is witnessing a rise in the number of uterine cancer cases. North America is expected to hold 46.5% of the global uterine cancer diagnostic testing market share in 2024. China has become a lucrative market for uterine cancer diagnostic testing providers because of a rise in government funding and healthcare spending. The market for uterine cancer diagnostic testing in China is projected to grow at a significant pace as a result of government reimbursement policies for women's health screenings and treatments.

What are Market Players Leveraging to Stay Ahead in the United States?

“Wide Availability of Affordable Diagnosis and Treatment Options”

Attribute	United States
Market Value (2024E)	US$ 1.35 Billion
Growth Rate (2024 to 2034)	5.7% CAGR
Projected Value (2034F)	US$ 2.36 Billion

Uterine cancer diagnostic testing market growth in the United States over the forecast period is projected to be driven by the availability of affordable diagnosis and treatment options. The increasing population of older women in the country is also a major driver for market growth.

• The National Institutes of Health claims that the United States has a high incidence of uterine cancer as a result of rising rates of post-menopausal women and an obese population brought on by unhealthy lifestyle choices.

Why is Demand for Uterine Cancer Diagnostic Testing Rising in Brazil?

“Demographic Shift toward Older Population”

Attribute	Brazil
Market Value (2024E)	US$ 60.39 Million
Growth Rate (2024 to 2034)	5% CAGR
Projected Value (2034F)	US$ 98.37 Million

Uterine cancer is one of the most common cancers among women in Brazil. Brazil has a sizable aging population, and as people age, so does their risk of developing uterine cancer. The increasing incidence and ensuing need for diagnostic testing are both influenced by the demographic shift towards an older population.

Category-wise Insights

The uterine cancer diagnostic testing market is categorized into endometrial carcinoma and uterine sarcoma in terms of cancer type, of which the former is expected to hold a 91.2% market share in 2024. By diagnostic test type, the market is segmented into ultrasound scanning, biopsy, and blood tests, of which biopsy is set to hold a market share of 56.1%.

In terms of end users, the market is divided into hospitals, ambulatory surgical centers, cancer research centers, specialized clinics, and diagnostic laboratories, of which the diagnostic laboratories are set to hold a market share of 41.3% in 2024.

Why is Ultrasound Scanning the Primary Choice for Assessing Uterine Abnormalities?

“Non-Invasive and Radiation-Free Nature of Ultrasound Scanning”

Attribute	Ultrasound Scanning
Segment Value (2024E)	US$ 1.33 Billion
Growth Rate (2024 to 2034)	8.2% CAGR
Projected Value (2034F)	US$ 2.49 Billion

The first imaging modality of choice for assessing uterine abnormalities is ultrasound scanning because it is non-invasive and radiation-free, thus reducing the discomfort for the patient and enabling more examinations when needed. Even in environments with limited resources, ultrasound equipment is widely accessible in healthcare settings, including clinics and hospitals. This is a key uterine cancer diagnostic testing market trend.

More people are opting for this because of its comparatively lower cost when compared to other imaging modalities. Ultrasonography gives doctors precise images of the uterus and its surrounding structures, enabling them to evaluate the uterus's size, texture, and shape as well as identify anomalies such as masses or tumors. To identify diseases such as endometrial cancer, it can also measure the thickness of the endometrium.

Why Do Diagnostic Laboratories Enjoy a Significant Share of the Market?

“Availability of Qualified Medical Professionals and Technologically Advanced Equipment”

Attribute	Diagnostic Laboratories
Segment Value (2024E)	US$ 1.33 Billion
Growth Rate (2024 to 2034)	7.3% CAGR
Projected Value (2034F)	US$ 2.69 Billion

Diagnostic laboratories are frequently outfitted with advanced technologies and specialized equipment needed for a variety of diagnostic tests, including those for uterine cancer. They act as centralized locations for the analysis of samples obtained from various healthcare settings (clinics, hospitals, etc.). Diagnostic laboratories have qualified medical personnel with specialized knowledge of accurately interpreting diagnostic tests, such as cytotechnologists, pathologists, and medical technologists. Rigorous quality standards are followed by accredited laboratories, guaranteeing accurate and consistent test results.

These labs provide a broad selection of diagnostic tests, such as molecular testing (genetic analysis, biomarker testing), histopathology (biopsies), cytology (Pap smears), and imaging (ultrasound, MRI). Uterine cancer and other conditions can be thoroughly evaluated thanks to this extensive test menu.

Competitive Landscape

Key players in the uterine cancer diagnostic testing market are focusing on research initiatives are in vitro diagnostic tools tailored for gynecological cancers. These efforts aim to improve early detection and treatment monitoring using novel liquid biopsy techniques centered around gynecological fluids.

• Women's health start-up MiMARK Diagnostics raised US$ 4.53 million in November 2023 in its first seed funding round. As per the company, the money will be used to further their research in gynecological diagnostics, with a particular emphasis on the non-invasive biomarker detection method using gynecological fluids. In 2021, the company was granted US$ 1.61 million by EIT Health. With a focus on enhancing the diagnosis of endometrial cancer, MiMARK is creating in vitro diagnostic tools for the management of gynecological cancers. This method places gynecological fluid at the center of the next stage of gynecological liquid biopsy.
• The United States FDA approved Roche Holding AG's VENTANA MMR RxDx Panel endometrial cancer diagnostic kit in April 2022. This kit is intended to diagnose patients who are suitable for anti-PD1 immunotherapy, which involves JEMPERLI (dostarlimab-gxly) monotherapy. When used in conjunction with chemotherapy, this test can help clinicians diagnose patients and offer women with MMR-deficient endometrial cancer new options for treatment.

Fact.MR provides detailed information about the price points of key uterine cancer diagnostic testing providers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this updated market report.

Segmentation of Uterine Cancer Diagnostic Testing Market Research

• By Cancer Type :

  • Endometrial Carcinoma
  • Uterine Sarcoma

• By Diagnostic Test :

  • Ultrasound Scanning
  • Biopsy
  • Blood Test

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Centers
  • Specialized Clinics
  • Diagnostic Laboratories
  • Others

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • East Asia
  • Latin America
  • South Asia & Pacific
  • Middle East & Africa